(MENAFN- EIN Presswire)
Pulmonary Arterial Hypertension Treatment Market
PORTLAND, OR, UNITED STATES, June 9, 2023/einpresswire.com / -- The Global pulmonary arterial hypertension market generated $7.2 billion in 2021, and is expected to reach $12 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031. The report provides an in-depth analysis of top segments, changing market trends, value chains, key investment pockets, competitive scenarios, and regional landscape. The report is an essential and helpful source of information for leading market players, investors, new entrants, and stakeholders in formulating new strategies for the future and taking steps to strengthen their position in the market.
Pulmonary arterial hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and can lead to heart failure if left untreated. The PAH treatment market refers to the various medications and therapies used to manage PAH symptoms and slow the progression of the disease.
📚 Get Your Sample Copy Here:
There are several classes of drugs used to treat PAH, including:
Endothelin receptor antagonists (ERAs)
Phosphodiesterase type 5 (PDE-5) inhibitors
Soluble guanylate cyclase (sGC) stimulators
In addition to medication, other treatments for PAH may include oxygen therapy, diuretics, and lifestyle changes such as exercise and a low-sodium diet.
The PAH treatment market is expected to continue to grow due to an increasing prevalence of the disease and the development of new therapies. Some of the major companies operating in this market include United Therapeutics Corporation, Bayer AG, Gilead Sciences, Inc., Johnson & Johnson. Clinical trials are also underway for new PAH treatments, including gene therapy and stem cell therapy.
Overall, while there is no cure for PAH, there are several treatments available to manage symptoms and slow the progression of the disease, and the PAH treatment market is expected to continue to grow in the coming years.
What is the Impact of Covid-19 Pandemic on Pulmonary arterial hypertension Market Globally?
The Covid-19 outbreak positively affected the market due to rise in prevalence of Covid-19 infactions with patients already suffering from pulmonary artery hypertension.
However, the diagnosis and treatment of pulmonary hypertension and observation of elevated mortality risk in individuals severely affected during the pandemic.
Procure Complete Report (200 Pages PDF with Insights, Charts, Tables,Figures)
The report segments the global pulmonary arterial hypertension market on the basis of drug type, type, route of administration, and region.
Based on drug type, the prostacyclin and prostacyclin analogs segment held the largest share in 2021, accounting for more than half of the market. In addition, the segment is estimated to register the highest CAGR of 5.5% during the forecast period.
On the basis of type, the branded segment dominated the market in terms of revenue in 2021, accounting for more than four-fifths of the market. However, the generics segment is estimated to register the highest CAGR of 5.7% from 2022 to 2031.
Based on route of administration, the oral segment held the largest share in 2021, accounting for nearly two-thirds of the market. In addition, the segment is projected to manifest the highest CAGR of 5.6% during the forecast period.
For Purchase Enquiry at:
The global pulmonary arterial hypertension market is analyzed across several regions such as North America, LAMEA, Asia-Pacific, and Europe. The market across North America held the lion's share in 2021, accounting for more than two-fifths of the market. However, the market across Asia-Pacific is expected to register the highest CAGR of 7.2% from 2022 to 2031.
The global pulmonary arterial hypertension market report includes an in-depth analysis of the prime market players such as Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc.
The report analyzes these key players in the global pulmonary arterial hypertension market. These players have adopted various strategies such as new product launches, expansion, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments of every market player.
KEY FINDINGS OF THE STUDY:
By drug type, the prostacyclin and prostacyclin analogs segment was the highest contributor to the pulmonary arterial hypertension treatment market share in 2021.
By type, the branded segment was the highest contributor to the market in 2021, and the generic segment is expected to continue this trend during the forecast period
Depending on route of administration, the oral segment was highest contributor in 2021 and is expected to grow at the fastest CAGR during the forecast period.
Trending Reports in Healthcare Industry:
Transcatheter Heart Valve Replacement Market Size:
Nanomedicine for Drug Delivery Market Share:
5933 NE Win Sivers Drive#205,
Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Allied Analytics LLP
email us here